Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Diagn Interv Imaging. 2020 Jan 13;101(6):355–364. doi: 10.1016/j.diii.2019.12.006

Table 4.

Complications experienced at 1 month in 219 patients who underwent transarterial chemoembolization of 353 hepatocellular carcinomas.

Complication
Fatigue 37 (37/219; 16.9%)
Pain requiring analgesics 15 (15/219; 6.8%)
Ascites development 15 (15/219; 6.8%)
Alopecia 5 (5/219; 2.3%)
Hepatic encephalopathy 5 (5/219; 2.3%)
Other 13 (13/219; 5.9%)

Variables are expressed as raw numbers. Numbers in parentheses are proportions followed by percentages.